Pediatric acute lymphoblastic leukemia (ALL) is the most common subtype of childhood
leukemia, which is characterized by the abnormal proliferation and accumulation of …

Treatment for relapsed acute lymphoblastic leukemia (ALL) in children and young adults
continues to evolve. Despite optimization of cytotoxic chemotherapeutic approaches and risk …

Advances in multi-agent chemotherapy and supportive care have dramatically improved
survival of children with B-cell acute lymphoblastic leukemia (B-ALL); however, patients with …

The 5-year survival rate for children and adolescents with acute lymphoblastic leukemia
(ALL) has improved to more than 90% in high-income countries. However, further increases …

Background: Acute lymphoblastic leukemia (ALL) is one of the most commonly diagnosed
cancers in children. Despite enormous efforts to treat ALL over the past decade, the intensity …

Acute lymphoblastic leukemia (ALL) is diagnosed in approximately 100 000 people
worldwide per year and 70% of the patients are children. Most children have a good …

Although the event-free survival for children and adolescents with acute lymphoblastic
leukemia (ALL) has dramatically improved over the past half century, it has plateaued over …

Although almost 90% of children with acute lymphoblastic leukemia (ALL) and∼ 60% of
children with acute myeloid leukemia are cured with frontline therapy, relapse and …

Novel therapies for pediatric acute lymphoblastic leukemia : Current Opinion in Pediatrics
Novel therapies for pediatric acute lymphoblastic leukemia : Current Opinion in Pediatrics Log …

Substantial progress has been made in the treatment of leukemia in childhood. Despite this,
leukemia remains a leading cause of pediatric cancer-related mortality and the prognosis is …